login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ERASCA INC (ERAS) Stock News
USA
-
Nasdaq
- NASDAQ:ERAS -
US29479A1088
-
Common Stock
3.19
USD
-0.1 (-3.04%)
Last: 12/4/2025, 8:17:42 PM
3.17
USD
-0.02 (-0.63%)
After Hours:
12/4/2025, 8:17:42 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ERAS Latest News, Press Relases and Analysis
All
Press Releases
9 days ago - By: Erasca, Inc.
Erasca to Present at the 8th Annual Evercore Healthcare Conference
15 days ago - By: FN Media Group LLC
- Mentions:
ONCY
ALXO
IMRX
PRLD
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
4 months ago - By: The Motley Fool
Erasca Narrows Loss 46% in Fiscal Q2
a year ago - By: BusinessInsider
ERAS Stock Earnings: Erasca Misses EPS for Q2 2024
22 days ago - By: Erasca, Inc.
Erasca Reports Third Quarter 2025 Business Updates and Financial Results
a month ago - By: Erasca, Inc.
Erasca to Present at Upcoming Conferences in November
a month ago - By: Zacks Investment Research
- Mentions:
THC
SEM
NVST
Will Lower Patient Days Affect Tenet Healthcare's Q3 Earnings?
2 months ago - By: Benzinga
- Mentions:
BOLT
COOP
WOOF
EFX
...
Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
2 months ago - By: Benzinga
- Mentions:
CIGL
DWTX
BOLT
UFG
...
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket
a year ago - By: InvestorPlace
ERAS Stock Earnings: Erasca Misses EPS for Q2 2024
4 months ago - By: Erasca, Inc.
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
6 months ago - By: Erasca, Inc.
Erasca to Present at Upcoming Investor Conferences in June
7 months ago - By: Erasca, Inc.
Erasca Reports First Quarter 2025 Business Updates and Financial Results
7 months ago - By: Erasca, Inc.
Erasca to Present at the Bank of America Securities Health Care Conference
7 months ago - By: Erasca, Inc.
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
8 months ago - By: Yahoo Finance
- Mentions:
PLTR
AAPL
USB
Is Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds?
8 months ago - By: Yahoo Finance
- Mentions:
MPC
PTLO
AMD
NVDA
...
Should You Consider Adding Marathon Petroleum Corporation (MPC) to Your Portfolio?
8 months ago - By: Yahoo Finance
- Mentions:
GERN
GOSS
CAN
GILD
...
Is Geron Corp. (NASDAQ:GERN) the Best Biotech Penny Stock to Buy According to Hedge Funds?
8 months ago - By: Erasca, Inc.
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
9 months ago - By: Erasca, Inc.
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
10 months ago - By: Erasca, Inc.
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
a year ago - By: Erasca, Inc.
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
a year ago - By: Erasca, Inc.
Erasca to Present at Upcoming Investor Conferences
a year ago - By: Erasca, Inc.
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
a year ago - By: Erasca, Inc.
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
a year ago - By: Erasca, Inc.
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
Please enable JavaScript to continue using this application.